Skip to main content
. 2016 Feb 9;7(12):13842–13853. doi: 10.18632/oncotarget.7283

Figure 7. Clorgyline, NMI or the combination with TMZ reduces tumor progression and increases the survival of TMZ-resistant tumors.

Figure 7

Athymic/nude mice were implanted intracranially with TMZ-resistant human glioma cells (U251R). Animals were then treated daily with: vehicle, TMZ (1 mg/kg), clorgyline (10 mg/kg), TMZ (1 mg/kg) + clorgyline (10 mg/kg), NMI (5 mg/kg), or TMZ (1 mg/kg) +NMI (5 mg/kg). MAO A inhibitors were administered subcutaneously daily for 21 days; TMZ treatment was given for the first 10 days only. A. Animals were imaged on days 7, 14, 21, 24 post-implantation. B. Graphic representation of bioluminescence imaging conducted at successive time points. C. The Kaplan-Meier survival curve shows that clorgyline significantly prolonged survival. E. The Kaplan-Meier survival curve for NMI and NMI+TMZ shows that NMI was effective alone, as compared to the vehicle, and the combination of NMI and TMZ was significantly more effective (*p < 0.001).